The trial aims to investigate the safety and efficacy of KUR-211 as an adjunct to standard of care in patients suffering from diabetic foot ulcers.
The study investigates the effects of KUR-211 applied twice a week for maximum 16 weeks in addition to standard of care versus standard of care (SOC) alone.
Kuros chief medical officer Virginia Jamieson said they look forward to reporting the results of this novel approach to the treatment of diabetic foot ulcers.